Journal of Lipid Research, Vol 31, 2001-2007, Copyright © 1990 by Lipid Research, Inc.

ARTICLES

Enhanced clearance from plasma of low density lipoproteins containing a truncated apolipoprotein, apoB-89

KG Parhofer, A Daugherty, M Kinoshita and G Schonfeld
Division of Atherosclerosis and Lipid Research, Washington University School of Medicine, St. Louis, MO 63110.

Previously we have reported on a kindred with hypobetalipoproteinemia in which three sisters were found to be compound heterozygotes for two newly described truncated forms of apoB. apoB-40 and apoB-89. ApoB-89- containing low density lipoproteins (LDL) bound with increased affinity to cultured normal human fibroblasts and were internalized and degraded at increased rates, suggesting that the low plasma concentrations of apoB-89-LDL of the patients could be due to enhanced rates of clearance through LDL-receptors. To examine this hypothesis, apoB-89-LDL was isolated from the three study subjects and apoB-100-LDL from two control subjects. LDL was conjugated to the radioiodinated residualizing label, dilactitol tyramine (*I-DLT, containing either 125I or 131I). *I-DLT-apoB-89-LDL and *I-DLT-apoB-100-LDL were simultaneously injected into ear veins of rabbits. The clearance from plasma and hepatic accumulations of both radiolabeled LDL fractions were followed over 24 h. Fractional catabolic rates (FCR) of apoB-89- LDL were 0.105 +/- 0.012 h-1 compared to 0.054 +/- 0.007 h-1 for apoB- 100-LDL. In agreement with the enhanced clearance from plasma, 1.72 to 1.87 times more *I-DLT-apoB-89-LDL than *I-DLT-apoB-100-LDL accumulated in the livers 24 h after injection. There was no significant difference in splenic accumulation, suggesting that LDL-receptors rather than scavenger receptors mediated the enhanced clearance of apoB-89-LDL. To assess further the importance of LDL-receptors, *I-DLT-apoB-89-LDL and *I-DLT-apoB-100-LDL were reductively methylated to inhibit their interactions with LDL-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. Schonfeld Familial hypobetalipoproteinemia: a review J. Lipid Res., May 1, 2003; 44(5): 878 - 883. [Abstract] [Full Text] [PDF]

				M. E. Hinsdale, P. M. Sullivan, H. Mezdour, and N. Maeda ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice J. Lipid Res., September 1, 2002; 43(9): 1520 - 1528. [Abstract] [Full Text] [PDF]

				J.-P. Wang, M. Enjoji, M. Tiebel, S. Ochsner, L. Chan, and B.-B. Teng Hammerhead Ribozyme Cleavage of Apolipoprotein B mRNA Generates a Truncated Protein J. Biol. Chem., August 20, 1999; 274(34): 24161 - 24170. [Abstract] [Full Text] [PDF]

				M. M. Veniant, E. Kim, S. McCormick, J. Boren, L. B. Nielsen, M. Raabe, and S. G. Young Insights into Apolipoprotein B Biology from Transgenic and Gene-Targeted Mice J. Nutr., February 1, 1999; 129(2): 451 - 451. [Abstract] [Full Text] [PDF]

				X.-F. Zhu, D. Noto, R. Seip, A. Shaish, and G. Schonfeld Organ Loci of Catabolism of Short Truncations of ApoB Arterioscler. Thromb. Vasc. Biol., June 1, 1997; 17(6): 1032 - 1038. [Abstract] [Full Text]

				M. Averna, S. M. Marcovina, D. Noto, T. G. Cole, E. S. Krul, and G. Schonfeld Familial Hypobetalipoproteinemia Is Not Associated With Low Levels of Lipoprotein(a) Arterioscler. Thromb. Vasc. Biol., December 1, 1995; 15(12): 2165 - 2175. [Abstract] [Full Text]

				J. Boren, U. Ekstrom, B. Agren, P. Nilsson-Ehle, and T. L. Innerarity The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100 J. Biol. Chem., March 16, 2001; 276(12): 9214 - 9218. [Abstract] [Full Text] [PDF]